Position in RPRX
as of Mar 31, 2026
· filed Apr 21, 2026
Position Value
$4,939,422
+$645,514 QoQ
Shares Held
102,969
-7.3% QoQ
Ownership
0.018%
of shares outstanding
% of Portfolio
0.28%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2022
8 quarters on record
Voting authority
Sole 85.16543814157659.ToString("F0")%
Shared 0.ToString("F0")%
None 14.83456185842341.ToString("F0")%
Common Shares in RPRX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Pallas Capital Advisors LLC holds $23,981,428 across 32 Biotechnology names. RPRX ranks #2 (20.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AXSM |
Axsome Therapeutics, Inc.
|
40,610 | $6,863,902 | |
| 2 | RPRX |
Royalty Pharma plc
This page
|
102,969 | $4,939,422 | |
| 3 | INCY |
Incyte Corp
|
33,157 | $3,120,736 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,680 | $2,070,675 | |
| 5 | EXEL |
Exelixis, Inc.
|
29,215 | $1,253,031 | |
| 6 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
2,212 | $731,884 | |
| 7 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,638 | $731,432 | |
| 8 | BMRN |
Biomarin Pharmaceutical Inc
|
12,396 | $700,250 |
All Filings in RPRX
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $4,939,422 | 102,969 | Shares | Sole | 2026-04-21 | |
| 2025-12-31 | $4,293,908 | 111,126 | Shares | Sole | 2026-01-14 | |
| 2025-09-30 | $3,689,652 | 104,582 | Shares | Sole | 2025-11-07 | |
| 2025-06-30 | $3,719,773 | 103,241 | Shares | Sole | 2025-07-09 | |
| 2025-03-31 | $3,126,915 | 100,447 | Shares | Sole | 2025-04-14 | |
| 2024-12-31 | $2,355,440 | 92,334 | Shares | Sole | 2025-01-13 | |
| 2023-03-31 | $755,981 | 20,982 | Shares | Sole | 2023-05-02 | |
| 2022-12-31 | $858,097 | 21,713 | Shares | Sole | 2023-01-24 | |
| No filing history on record for this holder in this stock. | ||||||